Etiological  treatment for infection by Trypanosoma cruzi

Neto, Vicente Amato

doi:10.1590/s0036-46651999000400001

Cited by 3 publications

(3 citation statements)

References 5 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the last 40 years only benznidazole and nifurtimox have been on the market and these drugs present many side effects and are poorly tolerated. Their use is restricted to the acute phase of the disease and long treatment courses are required [ 2 , 3 ]. For these reasons, the development of new safe and effective therapeutic agents is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Antiproliferative Effect and Ultrastructural Alterations Induced by Psilostachyin on Trypanosoma cruzi

Sülsen

Barrera

Muschietti³

et al. 2010

Molecules

View full text Add to dashboard Cite

The effect of psilostachyin, a natural sesquiterpene lactone, on the growth and viability of cultured epimastigotes of Trypanosoma cruzi (Tulahuen) is reported. The antiproliferative effect was evaluated by counting the parasites in a Neubauer chamber and measuring their viability by using the dye exclusion technique. The effect on parasite growth was irreversible at concentrations higher than 1.0 µg/mL and the addition of glutathione only partially blocked the effect of the compound. Moreover, we have studied the effects of this natural compound on parasite ultrastructure by transmission electron microscopy. Interestingly, psilostachyin induced ultrastructural alterations on the parasites at a concentration of 0.5 µg/mL, with important mitochondrial swelling and deformity of the kinetoplast.

show abstract

Section: Introductionmentioning

confidence: 99%

Antiproliferative Effect and Ultrastructural Alterations Induced by Psilostachyin on Trypanosoma cruzi

Sülsen

Barrera

Muschietti³

et al. 2010

Molecules

View full text Add to dashboard Cite

show abstract

“…2 The clinical treatment of chronic patients remains controversial, especially among indeterminate cases. 3 It is worth mentioning that vector control programs in Southern Cone countries in the past decade have markedly reduced the overall incidence of new infections 4 although large numbers of acute cases are still seen in some regions. 5 Furthermore, there is a need to treat about 5 million chronic chagasic patients and to prevent transmission of the disease through blood transfusion.…”

Section: Introductionmentioning

confidence: 99%

“…In the chronic phase, most patients remain asymptomatic (indeterminate phase), with about 20% of the cases developing irreversible cardiac, digestive, or neurologic disturbances . The clinical treatment of chronic patients remains controversial, especially among indeterminate cases . It is worth mentioning that vector control programs in Southern Cone countries in the past decade have markedly reduced the overall incidence of new infections although large numbers of acute cases are still seen in some regions .…”

Section: Introductionmentioning

confidence: 99%

A Trypanocidal Phenazine Derived from β-Lapachone

et al. 2002

View full text Add to dashboard Cite

An intensive effort has been directed toward finding alternative drugs for treatment of Chagas' disease, caused by Trypanosoma cruzi, and prophylaxis of blood in endemic areas. Our research comprises the synthesis and trypanocidal screening of derivatives from naphthoquinones. Herein a new phenazine, obtained from the reaction of beta-lapachone with aniline, has its structure established by physical data and X-ray analysis. It was 9 times more active against T. cruzi trypomastigotes than crystal violet.

show abstract

Estudo longitudinal e quimioterapia específica em crianças, com doença de Chagas crônica, residentes em área de baixa endemicidade da República Argentina

Streiger

Barco

Fabbro

et al. 2004

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Clinical and epidemiological results of 95 treated and untreated chronic chagasic children, with an up to 24 years follow-up period are presented. This population studied in the 1/14 age bracket, residing in Santa Fe city, Argentina, was diagnosed through Chagas-specific conventional serologic reactions. Clinical examination was supplemented with electrocardiogram, chest X-rays, and blood and urine tests for evaluating hepatic function. The drugs employed were nifurtimox or benznidazole. In post treatment period xenodiagnosis was made in 33 patients. Regarding Trypanosoma cruzi transmission, the studied individuals presented multi-risk antecedents: vectorial, congenital and/or blood transfusion. Among 24 untreated children 14 were controlled during 8/24 years: all this patients maintained the initial antibody concentration and clinical status. From 71 treated patients 49 were followed-up 4/24 years: 14 remained positive, 6 presented dubious results, and 29 showed final non-reactive results. 9 of this presented sometimes oscilating results. In 1/6 age bracket children, the serology turned negative after 3.5 years (median) once the treatment was finished, while patients treated in the 7/14 age bracket, the median of negativization was 8 years. 3.8% did not tolerate the drug. None of the groups changed their clinical condition. The untreated children did not change the serology. The percentage of treated children presenting negative serological results decrease according to the age when treatment was given: 75% became negative when treated at < or =4 years old and 43% when treated at > or =9 years old.

show abstract

Etiological treatment for infection by Trypanosoma cruzi

Cited by 3 publications

References 5 publications

Antiproliferative Effect and Ultrastructural Alterations Induced by Psilostachyin on Trypanosoma cruzi

Antiproliferative Effect and Ultrastructural Alterations Induced by Psilostachyin on Trypanosoma cruzi

A Trypanocidal Phenazine Derived from β-Lapachone

Estudo longitudinal e quimioterapia específica em crianças, com doença de Chagas crônica, residentes em área de baixa endemicidade da República Argentina

Contact Info

Product

Resources

About